Axonics (NASDAQ: AXNX)
Some price data may be temporarily unavailable.
Axonics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Axonics Company Info
Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.
News & Analysis
Why Shares of Axonics Rose Friday
The company showed improved revenue and margins in its second-quarter report.
Axonics: Buy at the High?
Axonics just hit its 52-week high, but the stock's momentum means that this high will likely be erased.
Medtronic's Bladder-Control Devices Have a Feisty New Competitor
The new rechargeable nerve stimulator from Axionics Modulation Technologies is giving the industry giant more competition than expected.
Why Axonics Modulation Technologies Is Skyrocketing 24.5% Today
A sneak peek at its fourth-quarter financial performance is fueling investors' optimism.
Why Axonics Modulation Technologies Stock Is Soaring Today
Shares jump after the medical device maker announces that it has secured an important regulatory win.
Why Axonics Modulation Technologies Stock Soared 63% in May
This medical device stock has been on a tear since the company's Halloween 2018 IPO.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.